-+ 0.00%
-+ 0.00%
-+ 0.00%

Phio Pharmaceuticals reports 65% pathological response rate in Phase 1b trial of PH-762 for cutaneous squamous cell carcinoma

Reuters·03/23/2026 11:04:38

Please log in to view news